Salarius Pharmaceuticals, Inc. - Common Stock (SLRX)

The market is filled with gapping stocks in Tuesday's session. Let's discover which stocks are showing gap-ups and gap-downs.

Before the opening bell on Tuesday, let's take a glimpse of the US markets and explore the top gainers and losers in today's pre-market session.

Discover the top movers in Monday's after-hours session and stay informed about the post-market dynamics.

Looking for insights into the US markets in the middle of the day on Wednesday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.

In today's session, there are notable price gaps in the US markets on Wednesday. Take a closer look at the stocks that are gap up and gap down.

As the regular session of the US market concludes on Tuesday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses.

Deal opportunities abound: KKR & Co.'s stake in Maya; DuPont's electronics business; Ingevity's North Charleston site; and S&W Seed Company.

Salarius Pharmaceuticals (NASDAQ: SLRX) shares are trading higher Monday after the company announced a merger agreement with Decoy Therapeutics, a privately held biopharmaceutical company.

SLRX stock results show that Salarius Pharmaceuticals beat analyst estimates for earnings per share the second quarter of 2024.